BD to Present at Barclays Global Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy BDX?
Source: PRnewswire
- Conference Announcement: BD will present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, at 8:30 AM Eastern Time, showcasing its latest advancements in medical technology, which is expected to attract significant attention from industry stakeholders.
- Live Webcast: The presentation will be accessible via BD's investor relations website, allowing global investors and healthcare professionals to gain real-time insights into the company's strategic direction and innovations, thereby enhancing corporate transparency.
- Company Overview: BD is one of the world's largest pure-play medical technology companies, employing over 60,000 people and delivering billions of products annually, committed to advancing healthcare through innovation that optimizes clinical operations and improves patient care.
- Strategic Objectives: BD's mission is to support frontline healthcare workers by developing transformative technologies and solutions aimed at lowering costs, increasing clinical efficiency, and improving safety, thereby expanding access to healthcare and solidifying its leadership position in the global medical market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 165.460
Low
157.00
Averages
192.64
High
232.00
Current: 165.460
Low
157.00
Averages
192.64
High
232.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through four segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems and BD Interventional. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Becton Dickinson Executive Affirms Ongoing Focus on Tuck-In M&A in High-Growth Sectors at Barclays Conference
- Company Strategy: Becton Dickinson's CEO has stated that the company will continue to pursue tuck-in mergers and acquisitions as part of its growth strategy.
- Focus Areas: The company is particularly focused on high-growth areas to enhance its market position and drive future success.
See More
Impressive Dividend Stocks in Healthcare Sector
- Becton, Dickinson's Dividend King Status: Becton, Dickinson has increased its dividend for over 50 years, earning its place as a Dividend King; despite recent struggles, its new product pipeline is expected to drive recovery, and the current 2.4% yield attracts long-term investors.
- Growth Potential in Medical Devices: Medtronic is just a few years away from Dividend King status, boasting a 2.9% dividend yield that is even more appealing; although facing challenges, the company has just begun selling surgical robots in the U.S., which is anticipated to provide significant growth opportunities.
- Valuation Discrepancies: Medtronic's P/E ratio stands at 27x, compared to the 63x of surgical robotics leader Intuitive Surgical, suggesting that the market may reward Medtronic with a higher valuation due to its advancements in surgical robotics, reflecting the potential of its diversified business.
- Low Investment Threshold: Investors can buy 5 shares of Becton, Dickinson or 10 shares of Medtronic for just $1,000, making both stocks reliable dividend options that currently have catalysts that may spur higher market valuations.
See More
Dividend Potential of Becton, Dickinson and Medtronic in Healthcare Sector
- Becton's Dividend History: Becton, Dickinson has increased its dividend for over 50 years, achieving a 2.4% yield, making it a solid investment choice in the healthcare sector; despite recent underperformance, its new product pipeline is expected to drive future growth.
- Medtronic's Growth Potential: Medtronic is on the verge of becoming a Dividend King with a 2.9% yield, having just launched surgical robots in the U.S. market, which is anticipated to create significant growth opportunities, particularly in the high-valuation surgical robotics sector.
- Low Investment Threshold: Investors can buy 5 shares of Becton or 10 shares of Medtronic for just $1,000, making these stocks ideal for small investors, especially given the current bearish market sentiment.
- Market Reaction Expectations: Although Becton was not recommended by The Motley Fool as a top investment, its long-standing dividend record and upcoming new products may attract long-term investors, particularly against the backdrop of sustained demand in the medical device industry.
See More
BD Receives CE Mark for Revello™ Vascular Stent
- CE Mark Achievement: BD announced that its Revello™ vascular stent has received CE marking, representing a significant advancement in the treatment of atherosclerotic lesions in common and external iliac arteries, which is expected to enhance the company's competitive position in the European market significantly.
- Technological Innovation: The Revello™ stent combines the flexibility of a self-expanding nitinol stent with radial resistive strength tailored for iliac arteries, featuring an ultra-thin expanded polytetrafluoroethylene coating designed to keep arteries open while minimizing trauma to healthy vascular segments, thereby improving patient outcomes.
- Clinical Trial Support: The ongoing AGILITY clinical trial, led by Dr. Sean Lyden from the Cleveland Clinic, evaluates the performance of Revello™ in patients with peripheral artery disease, providing crucial data to support the clinical application of the stent and enhancing physician confidence in the product.
- Market Launch Strategy: The Revello™ stent will be launched in European countries that accept CE marking, while in the U.S., it remains an investigational device limited to research use, a market strategy that will help BD establish a strong product foundation in Europe and drive future sales growth.
See More
BD Receives CE Mark for Revello™ Vascular Covered Stent
- CE Mark Achievement: BD announced that its Revello™ Vascular Covered Stent has received CE marking, a significant advancement aimed at treating peripheral artery disease in the aging EU population, which is expected to enhance the company's competitive position in the European market.
- Technological Innovation: The Revello™ stent combines the flexibility of a self-expanding Nitinol stent with radial resistance tailored for iliac arteries, designed to improve treatment outcomes and reduce complication risks, thereby enhancing physicians' capabilities in complex cases.
- Clinical Research Support: The clinical performance of the stent is being evaluated in the AGILITY multicenter study led by the Chair of Vascular Surgery at Cleveland Clinic, which is expected to provide robust data to support its market launch and further solidify BD's leadership in peripheral vascular treatments.
- Market Launch Strategy: The Revello™ stent will be introduced in countries accepting the CE mark, anticipated to generate new revenue streams for BD while increasing its influence in the global medical device market, particularly in the rapidly growing European sector.
See More
BD Launches New Revello™ Vascular Stent
- CE Mark Approval: BD announced that its Revello™ vascular stent has received CE marking, marking a significant advancement in treating lower limb arterial diseases, which is expected to greatly enhance physicians' capabilities in managing complex cases and meet the growing market demand.
- Technological Innovation: The Revello™ stent combines a self-expanding nitinol structure with radial resistance suitable for iliac arteries, designed to improve vessel patency while reducing the risk of trauma to healthy vascular segments, thereby enhancing patient treatment outcomes and safety.
- Clinical Trial Support: The ongoing AGILITY clinical trial, led by experts from the Cleveland Clinic, aims to evaluate the stent's performance in patients with peripheral artery disease, further validating its clinical application effectiveness.
- Market Launch Plan: The Revello™ stent will be launched in European countries accepting CE marking, which is expected to strengthen BD's competitiveness in the European market, while it remains experimental in the U.S., limiting its usage scope.
See More
Becton Dickinson Executive Affirms Ongoing Focus on Tuck-In M&A in High-Growth Sectors at Barclays Conference
- Company Strategy: Becton Dickinson's CEO has stated that the company will continue to pursue tuck-in mergers and acquisitions as part of its growth strategy.
- Focus Areas: The company is particularly focused on high-growth areas to enhance its market position and drive future success.
See More
Impressive Dividend Stocks in Healthcare Sector
- Becton, Dickinson's Dividend King Status: Becton, Dickinson has increased its dividend for over 50 years, earning its place as a Dividend King; despite recent struggles, its new product pipeline is expected to drive recovery, and the current 2.4% yield attracts long-term investors.
- Growth Potential in Medical Devices: Medtronic is just a few years away from Dividend King status, boasting a 2.9% dividend yield that is even more appealing; although facing challenges, the company has just begun selling surgical robots in the U.S., which is anticipated to provide significant growth opportunities.
- Valuation Discrepancies: Medtronic's P/E ratio stands at 27x, compared to the 63x of surgical robotics leader Intuitive Surgical, suggesting that the market may reward Medtronic with a higher valuation due to its advancements in surgical robotics, reflecting the potential of its diversified business.
- Low Investment Threshold: Investors can buy 5 shares of Becton, Dickinson or 10 shares of Medtronic for just $1,000, making both stocks reliable dividend options that currently have catalysts that may spur higher market valuations.
See More
Dividend Potential of Becton, Dickinson and Medtronic in Healthcare Sector
- Becton's Dividend History: Becton, Dickinson has increased its dividend for over 50 years, achieving a 2.4% yield, making it a solid investment choice in the healthcare sector; despite recent underperformance, its new product pipeline is expected to drive future growth.
- Medtronic's Growth Potential: Medtronic is on the verge of becoming a Dividend King with a 2.9% yield, having just launched surgical robots in the U.S. market, which is anticipated to create significant growth opportunities, particularly in the high-valuation surgical robotics sector.
- Low Investment Threshold: Investors can buy 5 shares of Becton or 10 shares of Medtronic for just $1,000, making these stocks ideal for small investors, especially given the current bearish market sentiment.
- Market Reaction Expectations: Although Becton was not recommended by The Motley Fool as a top investment, its long-standing dividend record and upcoming new products may attract long-term investors, particularly against the backdrop of sustained demand in the medical device industry.
See More
BD Receives CE Mark for Revello™ Vascular Stent
- CE Mark Achievement: BD announced that its Revello™ vascular stent has received CE marking, representing a significant advancement in the treatment of atherosclerotic lesions in common and external iliac arteries, which is expected to enhance the company's competitive position in the European market significantly.
- Technological Innovation: The Revello™ stent combines the flexibility of a self-expanding nitinol stent with radial resistive strength tailored for iliac arteries, featuring an ultra-thin expanded polytetrafluoroethylene coating designed to keep arteries open while minimizing trauma to healthy vascular segments, thereby improving patient outcomes.
- Clinical Trial Support: The ongoing AGILITY clinical trial, led by Dr. Sean Lyden from the Cleveland Clinic, evaluates the performance of Revello™ in patients with peripheral artery disease, providing crucial data to support the clinical application of the stent and enhancing physician confidence in the product.
- Market Launch Strategy: The Revello™ stent will be launched in European countries that accept CE marking, while in the U.S., it remains an investigational device limited to research use, a market strategy that will help BD establish a strong product foundation in Europe and drive future sales growth.
See More
BD Receives CE Mark for Revello™ Vascular Covered Stent
- CE Mark Achievement: BD announced that its Revello™ Vascular Covered Stent has received CE marking, a significant advancement aimed at treating peripheral artery disease in the aging EU population, which is expected to enhance the company's competitive position in the European market.
- Technological Innovation: The Revello™ stent combines the flexibility of a self-expanding Nitinol stent with radial resistance tailored for iliac arteries, designed to improve treatment outcomes and reduce complication risks, thereby enhancing physicians' capabilities in complex cases.
- Clinical Research Support: The clinical performance of the stent is being evaluated in the AGILITY multicenter study led by the Chair of Vascular Surgery at Cleveland Clinic, which is expected to provide robust data to support its market launch and further solidify BD's leadership in peripheral vascular treatments.
- Market Launch Strategy: The Revello™ stent will be introduced in countries accepting the CE mark, anticipated to generate new revenue streams for BD while increasing its influence in the global medical device market, particularly in the rapidly growing European sector.
See More
BD Launches New Revello™ Vascular Stent
- CE Mark Approval: BD announced that its Revello™ vascular stent has received CE marking, marking a significant advancement in treating lower limb arterial diseases, which is expected to greatly enhance physicians' capabilities in managing complex cases and meet the growing market demand.
- Technological Innovation: The Revello™ stent combines a self-expanding nitinol structure with radial resistance suitable for iliac arteries, designed to improve vessel patency while reducing the risk of trauma to healthy vascular segments, thereby enhancing patient treatment outcomes and safety.
- Clinical Trial Support: The ongoing AGILITY clinical trial, led by experts from the Cleveland Clinic, aims to evaluate the stent's performance in patients with peripheral artery disease, further validating its clinical application effectiveness.
- Market Launch Plan: The Revello™ stent will be launched in European countries accepting CE marking, which is expected to strengthen BD's competitiveness in the European market, while it remains experimental in the U.S., limiting its usage scope.
See More
